Cellseed Inc. · TSE:7776
Cellseed — FY2021 Earnings Presentation
29 slides from Cellseed's earnings presentation, Feb 22, 2022
Slide 1: Fiscal 2021 Earnings Results Presentation
CellSeed Inc. Fiscal 2021 Earnings Results Presentation JASDAQ Growth Stock Code:7776
Slide 2: Contents
Contents Company Profile Financial summary FY 12/2021 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 1
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: Our Business Model
Our Business Model Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partn
Slide 5: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering Copyright © CellSeed Inc. All Rights Reserved. 4
Slide 6: Contents
Contents Company Profile Financial summary FY 12/2021 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 5
Slide 7: Financial summary FY 12/2021
Financial summary FY 12/2021 FY2020 Consolidated FY2021 Consolidated （January 2020 – （January 2021 - December 2021） December 2020） Change from Amount Change Amount Previous Period （Millions of Yen） （Millions of Yen） （Millions of Yen） （%） Net sales 161 -37 18.9 199 Operating profit -864 -145 － -719 O
Slide 8: Issuance of the 22nd stock acquisition rights
Issuance of the 22nd stock acquisition rights (including a provision for exercise price revision) by third-party allotment Allocation date January 5, 2022 Number of stock acquisition rights 44,000 issued Exercised by Barclays Bank PLC Amount of funds 854,919,800 yen (approx. amount of deduction take
Slide 9: Contents
Contents Company Profile Financial summary FY 12/2021 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 8
Slide 10: Cell cultureware in the regenerative medicine supporting business
Cell cultureware in the regenerative medicine supporting business Professor Okano of Tokyo Women’s Medical Temperature-responsive cell cultureware 1989 University invented temperature-responsive cell cultureware. invented by Professor Okano of Tokyo 2004 Released RepCell® and HydroCell® Women's Medi
Slide 11: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell® This cultureware In addition to the same maintains the characteristics as those physiological activity of of UpCell®, this cells and retains a high cultureware allows for level of antigen proteins the recovery of cells in a on t
Slide 12: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Recently, the production of bio-pharmaceutical products using mass-cultured cells, the immunotherapy using cells, and initiatives for solving food and environmental issues have been active. In the generally used cell collection technology, proteolytic
Slide 13: Provision of consistent quality and services
Provision of consistent quality and services Cellseed has acquired and currently maintain the following certifications in order to provide consistent quality and services. Maintenance of ISO9001 certification Permission to manufacture specific processed cells • Date of registration • Date of reg
Slide 14: Head office, CPC, New development and manufacturing facility
Head office・CPC・New development and manufacturing facility Time 24 Aomi Cell Cultureware Innovation Center Time 24 Building, 4-32, Aomi 2-chome, Koto-ku, Tokyo CellSeed Haneda Airport Telecom Center Sta. Head Office 15F (East Wing) Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo Cell Processing
Slide 15: New development and manufacturing facility
New development and manufacturing facility Name of Aomi Cell Cultureware Innovation Center facility Scope of the Development and manufacturing of the business flask products Equipment product Equipment analysis room warehouse Copyright © CellSeed Inc. All Rights Reserved. 14
Slide 16: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products Development of cell sheet manufacturing methods Contract manufacturing of cell sheet products Quality testing of cell sheets, etc. Facility Management and Applica
Slide 17: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service For the regenerative medicine service, we obtained the permission to manufacture specific processed cells (facility No. FA3160008) in March 2017 and the permission to manufacture products for regenerative medicine in October 2018 and have un
Slide 18: The 2nd Cell Sheet Engineering Innovation Forum
The 2nd Cell Sheet Engineering Innovation Forum The 2nd Forum on Cell Sheet Engineering Innovation Forum was held online on November 1, 2021 with participation from many people throughout Japan. Through the forum, we created an environment where participants could interact online and have lively dis
Slide 19: Annual changes in patent applications and academic papers
Annual changes in the number of patent applications and submitted academic papers related to cell sheet engineering Obtained approval for Obtained approval for Ocural (J-TEC) Obtained conditional Nepic (J-TEC) approval for Terumo 60 HeartSheet🄬 180 160 No. of academic papers submitted 出願 Patent 論⽂…
Slide 20: The 2nd Cell Sheet Engineering Innovation Forum
The 2nd Cell Sheet Engineering Innovation Forum Theme Research on "cell sheet", "temperature-responsive cell culture equipment" and peripheral technologies Best Poster Award Kazuyoshi YAMAZAKI（Hokkaido University） Innovation award Ryuichiro Tanaka（Tokyo Women's Medical University） Poster
Slide 21: Regenerative medicine pipeline progress
パイプラインの進捗状況 Regenerative medicine The Act on the Safety of The Act on Pharmaceuticals Regenerative Medicine and Medical Devices Self-funded Clinical Manufacturing medical research and sales treatment Fundamental Clinical Clinical trials Application Pipeline Sales research research First phase Second
Slide 22: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D) A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) Cell sheet is on a temperature-responsive cell culture ware and then
Slide 23: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Womenʼs Medical Univ. 10case Tokyo Womenʼs Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 24: Chondrocyte Sheet
Chondrocyte Sheet Disease characteristics • Causes︓ageing・obesity traumatic • No treatment to regenerate lost cartilage is available In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms. Autologous chondrocyte sheets Allogeneic c
Slide 25: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets 2017 Clinical Research at Tokai University | 2019 Completed in December 2019 transplants of 10 cases 2018 Adopted as the ancillary project of AMED Adopted as “a project for developing fundamental evaluation technologies for industrializing regenerative | medicine (suppo
Slide 26: Industry-academia collaboration in allogeneic cartilage cell sheets
<Allogeneic cells> Industry-academia collaboration in cartilage cell sheets 2017 2018 2019 2020 2021 2022 2023 2024 Tokai Univ. Clinical research Follow-up to 10 cases clinical research Clinical trials for allogeneic chondrocyte cell sheets Project to Support Seeds Development AMED Submission trial
Slide 27: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets Collection Cell Seeding / Subculture / Cryopreservation of tissue suspension culture culture Quality/Safety Evaluation test Polydactyly Primary Xth passage donors cultured cells cell Unzip when needed Preparation of Cell Bank Seeding / Manufacture Transport culture cell
Slide 28: Allogeneic chondrocyte cell sheets: cell bank and clinical trial products
Allogeneic chondrocyte cell sheets: Construction of cell bank, manufacturing of clinical trial products Receipt of commercial Grasping the number of Manufacturing Construction of cell bank tissue passages and changes and evaluation Creation of stock in characteristics of cell bank Optimization of
Slide 29: This presentation is made by CellSeed Inc. solely for the disclosure of the financial
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © CellSeed Inc. All Rights Reserved.